Urinary Tract Obstruction Treatment Devices Market Report 2025

This Urinary Tract Obstruction Treatment Devices market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The urinary tract obstruction (UTO) treatment devices market size has grown strongly in recent years. It will grow from $1.32 billion in 2024 to $1.41 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth during the historic period can be attributed to factors such as the increasing prevalence of urological conditions, a growing demand for advanced treatment solutions, a rise in the adoption of minimally invasive techniques, an increasing need for advanced catheter and stent technologies, and a heightened focus on robotic-assisted surgeries.

The urinary tract obstruction (UTO) treatment devices market size is expected to see strong growth in the next few years. It will grow to $1.8 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth during the forecast period can be attributed to factors such as the rising prevalence of urological conditions, a growing demand for personalized treatment options, increased adoption of robotic-assisted surgeries, and heightened healthcare awareness among patients. Key trends in the forecast period include advancements in minimally invasive technologies, the development of more efficient and less painful treatment options, innovations in materials, and the integration of advanced imaging and diagnostic tools.

The growing incidence of kidney disease is projected to drive the expansion of the urinary tract obstruction treatment devices market. Kidney disease refers to conditions that impair the kidneys' ability to filter waste and excess fluids from the blood. This rise in kidney disease is linked to factors such as an aging population, higher rates of diabetes and hypertension, and poor lifestyle choices. As kidney disease progresses, urinary tract obstructions become more frequent, creating a demand for devices that help manage these blockages and prevent further kidney damage. For example, a report from Kidney Research UK, published in June 2023, revealed that about 7.2 million people in the UK currently suffer from chronic kidney disease, which makes up over 10% of the population. Of these, 3.25 million are in the advanced stages, while 3.9 million are in earlier stages. By 2033, the number of people with chronic kidney disease is expected to reach 7.61 million. Consequently, the rising prevalence of kidney disease is anticipated to drive market growth in urinary tract obstruction treatment devices.

Leading companies in the urinary tract obstruction treatment devices market are focusing on creating innovative products, such as intermittent urological catheters, to offer long-term solutions for managing urinary tract blockages. Intermittent urological catheters are used to drain urine from the bladder temporarily in patients who cannot urinate naturally. These catheters help prevent complications such as urinary tract infections, bladder damage, and kidney problems by ensuring the bladder is regularly emptied. For example, in August 2022, Otsuka Pharmaceutical Factory, Inc., a pharmaceutical company based in Japan, introduced the OT-Balloon Catheter. This reusable catheter is designed for patients who have difficulty urinating on their own. It stays in the bladder temporarily by inflating a balloon at its tip, allowing for self-catheterization and reducing the need for frequent reapplication. This launch reflects Otsuka’s ongoing efforts to improve patient care by offering solutions that enhance independence in managing urinary needs.

In December 2022, Alleima, a Swedish producer of advanced materials and industrial products, acquired Endosmart Gesellschaft für Medizintechnik GmbH for an undisclosed amount. This acquisition enables Alleima to bolster its position in the medical sector, improve its nitinol processing capabilities, and broaden its product offerings to meet the rising demand in urology. Endosmart Gesellschaft für Medizintechnik GmbH, based in Germany, specializes in the development and manufacturing of medical devices for urological applications.

Major players in the urinary tract obstruction treatment devices market are Medtronic Plc, Becton Dickinson and Company, Stryker Corporation, Boston Scientific Corporation, Olympus Corporation, Coloplast Corporation, Smiths Group plc, Bio-Rad Laboratories, Teleflex Incorporated, Paul Hartmann AG, Karl Storz SE & Co. KG, Cook Medical, Hollister Incorporated, Amsino International Inc., Richard Wolf GmbH, Braun Melsungen AG, Angiplast Pvt. Ltd., Mais India Medical Devices Pvt. Ltd., Convatec Inc., VYGON (UK) LTD., United Endoscopy, Advin Health Care, Manish Medi Innovation, MicroPort Urocare (Jiaxing) Co. Ltd., and Nikotech Pvt Ltd.

North America was the largest region in the urinary tract obstruction treatment devices market in 2024. The regions covered in urinary tract obstruction (UTO) treatment devices report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the urinary tract obstruction (UTO) treatment devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Urinary tract obstruction (UTO) treatment devices are medical tools designed to manage blockages that hinder the normal flow of urine from the kidneys to the bladder. These devices help remove obstructions, drain urine, or assist in the healing process, relieving pressure and preventing further damage to the kidneys, bladder, and urinary tract.

The primary types of UTO treatment devices include urinary catheters, ureteroscopes, shock wave lithotripters, laser therapy systems, and others. Urinary catheters are flexible tubes inserted into the bladder to drain urine, helping manage urinary obstructions and preventing complications such as bladder overdistension. These devices are used in a variety of applications, including treating cancers, stones, benign prostatic hyperplasia (BPH), and hydronephrosis, and are utilized by various end users such as hospitals, ambulatory surgical centers, surgical centers, and other healthcare facilities.

The urinary tract obstruction treatment devices market research report is one of a series of new reports that provides urinary tract obstruction treatment devices market statistics, including the urinary tract obstruction treatment devices industry global market size, regional shares, competitors with the urinary tract obstruction treatment devices market share, detailed urinary tract obstruction treatment devices market segments, market trends, and opportunities, and any further data you may need to thrive in the urinary tract obstruction treatment devices industry. These urinary tract obstruction treatment devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The urinary tract obstruction (UTO) treatment devices market consists of sales of ureteral stents, nephrostomy tubes, suprapubic catheters, and percutaneous nephrostomy kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.